Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Valeriano Di Domenico)

Up­dat­ed: Bio­gen sells just $300K worth of Aduhelm in Q3, as ques­tions on long-term vi­a­bil­i­ty re­main

Bare­ly any­one is ac­cess­ing Bio­gen’s con­tro­ver­sial Alzheimer’s treat­ment, with the com­pa­ny re­port­ing just $0.3 mil­lion in Aduhelm sales in the third quar­ter. Al­though in­vestors will be look­ing to the longer term, when CMS may de­cide to cov­er the drug and open the flood­gates for more re­im­burse­ment, use of the drug is cur­rent­ly stalled.

Since June, when the FDA first signed off on the drug un­der its ac­cel­er­at­ed path­way, Bio­gen said Wednes­day that it’s sold a to­tal of $2 mil­lion worth of Aduhelm. That’s a far cry from the peak Wall Street sales es­ti­mate of about $9 bil­lion in an­nu­al sales, and even a ways away from the sell-side con­sen­sus of about $17 mil­lion in Q3 sales.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.